A multicenter randomized phase Ⅱ trail of Oxaliplatin in the patients with colorectal cancer

Objective： To evaluate the efficacy and safety of Oxaliplatin in the patients with colorectal cancer. Methods： In a multicenter randomized control study, a total of 144 patients were divided into four groups： Oxaliplatin （Haitong） ＋ 5-FU, CF （group A） 41 cases; 5-FU ＋ CF （group B） 41 cases; Oxaliplatin （Haitong） ＋ 5-FU, CF （group C） 31 cases; Oxaliplatin （positive drug） ＋ 5-FU ＋ CF （group D） 31 cases. Oxaliplatin combination regimen： L-OHP 130 mg/m2 i.v. infusion 2 h dl; CF 200 mg/m2 i.v. 2 h d1-d5; 5-FU 300 mg/m2 i.v. infusion 4 h d1-d5 （after CF）. 5-FU ＋ CF combination regimen： CF 200 mg/m^2 i.v. infusion 2 h d1-d5, 5-FU 300 mg/m^2 i.v. infusion 4h d1-d5 （after CF）, the schedule was repeated every 3 weeks. The total cycles were 3. Results： After three circles treatment, overall response rate of 4 groups was 24.4% （group A）, 2.4% （group B）, 25.8% （group C） and 19.4% （group D）, respectively. The response rate was significantly different between group A and group B （P 〈 0.01）, but no significant difference was observed between group C and group D （P 〉 0.05）. Conclusion： The Oxaliplatin （Haitong） for injection combination regimen is effective in the treatment of celorectal cancer.

A multicenter randomized phase II trail of Oxaliplatin in the patients with colorectal cancer

Objective To evaluate the efficacy and safety of Oxaliplatin in the patients with colorectal cancer. Methods In a multicenter randomized control study, a total of 144 patients were divided into four groups: Oxaliplatin (Haitong) + 5-FU, CF (group A) 41 cases; 5-FU + CF (group B) 41 cases; Oxaliplatin (Haitong) + 5-FU, CF (group C) 31 cases; Oxaliplatin (positive drug) + 5-FU + CF (group D) 31 cases. Oxaliplatin combination regimen: L-OHP 130 mg/m² i.v. infusion 2 h d1; CF 200 mg/m² i.v. 2 h d1–d5; 5-FU 300 mg/m² i.v. infusion 4 h d1–d5 (after CF). 5-FU + CF combination regimen: CF 200 mg/m² i.v. infusion 2 h d1–d5, 5-FU 300 mg/m² i.v. infusion 4h d1–d5 (after CF), the schedule was repeated every 3 weeks. The total cycles were 3. Results After three circles treatment, overall response rate of 4 groups was 24.4% (group A), 2.4% (group B), 25.8% (group C) and 19.4% (group D), respectively. The response rate was significantly different between group A and group B (P < 0.01), but no significant difference was observed between group C and group D (P > 0.05). Conclusion The Oxaliplatin (Haitong) for injection combination regimen is effective in the treatment of colorectal cancer.